Transfer from: ammonia-based observation In the area of innovative medicines, the presence of risk-takings has always been encouraged. In the face of “nothing”, it is the core capacity of a pharmacological business to find a spectacular path through aggressive attacks. This has also been the core story of K medicine over the past few years. There has been no drop in salvation of K medicines in the yardstick that continues to be coloured, and the gold baggage of the JCP has been sought. The ne...